Cantargia AB (“Cantargia”) of Lund, Sweden, and Panorama Research
Inc.
(“Panorama”), a California based specialist antibody developer, have
entered
into a collaboration agreement to jointly accelerate Cantargia's second
program
directed towards autoimmune and inflammatory diseases. Cantargia’s
proprietary
antibodies, against the molecular target IL1RAP, will be affinity
matured and
humanized using Panorama’s proprietary technology. In addition,
Panorama will
generate cell lines optimized for high level GMP production.
Cantargia will be
responsible for subsequent down-stream development. Under the
terms of the
agreement, Panorama will share risk in the project in exchange for
a fraction of
future incomes from third parties or future sales.
Cantargia has
recently initiated a second project, CANxx, The purpose is to
develop a
therapeutic candidate blocking the activity of inflammatory cytokines,
such as
IL-33 or IL-36, through the molecular target IL1RAP. Cantargia will
provide
proprietary prototype antibodies, which will be further optimized to
obtain
desired properties. Panorama has significant and well-documented
experience to
optimize and humanize monoclonal antibodies and will invest in the
project by
contributing their knowledge and labour in exchange for a fraction of
future
revenue. In addition, Panorama will also develop a cell line for GMP
production
of the first product candidate identified. Cantargia will be
responsible for
preclinical and clinical development as well as for GMP
production. Panorama’s
fraction of the project is defined in the contract and is
proportional to the
contribution along the project life span. Thereby Panorama
is entitled to a
single digit fraction of payments from potential future
partners. Panorama’s
percentage will decrease as the project passes predefined
development
milestones.

“This partnership is of major importance for Cantargia, it means
that our lead
project CAN04 for cancer treatment as well as our second project
CANxx, both are
financed according to plan”, Göran Forsberg, CEO of Cantargia,
said. “The
recognition from renowned Panorama demonstrates the interest from
the
international community in our assets. We look forward to continue
the
development of CANxx and foresee synergies between our
organizations.”

“There is a clear potential to use antibodies against the
molecular target
IL1RAP to treat a large number of serious diseases”, said
James W Larrick, CEO
and founder of Panorama, “We are excited to be both a
development partner and
investor in this important program”.

Panorama is a
privately-owned biomedical research and development holding
company. Panorama
is based in a ~45,000 sq. ft. state-of-the art laboratory
located in the heart
of Silicon Valley California. Panorama has a staff of 20
medical scientists (15
with MD and/or PhD degrees) with life science expertise
in medicinal chemistry,
pharmacology, molecular biology and cell biology.
Panorama has discovered and
served as an incubator for a number of technologies
and pharmaceutical projects
that subsequently were licensed to development
partners or incorporated into
Panorama portfolio companies. For more
information, see www.pano.com.

For
further information, please contact
Göran Forsberg, CEO
Telephone: +46
(0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This constitutes
information that Cantargia is required to publish under the
EU’s Market Abuse
Regulation. The information was submitted for publication
through the above
contact person on 16 June 2017, at 8.30am.

About Cantargia

Cantargia AB
(publ), reg.no. 556791-6019, is a biotech company that is
developing an
antibody-based cancer treatment, which aims to attack cancer cells
and arrest
the inflammation of the tumour. The original discovery by the
research team
behind Cantargia was the overexpression of a specific target
molecule,
interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem
cells in
patients with leukemia that is not found in normal stem cells in the
bone
marrow. In preclinical studies (in vitro and in vivo) the antibody,
targeted at
IL1RAP, has been shown to have two potential mechanisms of action,
which are
complementary. The Company has selected a product candidate, CAN04,
for future
studies in humans and development activities have been focused on non
-small
cell lung cancer and pancreatic cancer.

Cantargia is listed on Nasdaq
Stockholm First North (ticker: CANTA). Sedermera
Fondkommission is the
company’s Certified Adviser. More information about
Cantargia is available at
http://www.cantargia.com.